abrdn plc Purchases 70,618 Shares of LivaNova PLC (NASDAQ:LIVN)

abrdn plc lifted its stake in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 43.8% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 232,025 shares of the company's stock after purchasing an additional 70,618 shares during the period. abrdn plc owned 0.43% of LivaNova worth $12,191,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. State of Alaska Department of Revenue raised its holdings in shares of LivaNova by 7.3% in the 3rd quarter. State of Alaska Department of Revenue now owns 6,246 shares of the company's stock valued at $328,000 after purchasing an additional 425 shares during the period. Allspring Global Investments Holdings LLC raised its stake in LivaNova by 3.3% in the third quarter. Allspring Global Investments Holdings LLC now owns 797,284 shares of the company's stock valued at $41,889,000 after buying an additional 25,277 shares during the period. Mitsubishi UFJ Asset Management UK Ltd. lifted its position in shares of LivaNova by 11.8% in the third quarter. Mitsubishi UFJ Asset Management UK Ltd. now owns 19,000 shares of the company's stock valued at $998,000 after buying an additional 2,000 shares during the last quarter. Diversified Trust Co boosted its stake in shares of LivaNova by 7.9% during the 3rd quarter. Diversified Trust Co now owns 15,007 shares of the company's stock worth $788,000 after acquiring an additional 1,105 shares during the period. Finally, Central Pacific Bank Trust Division acquired a new position in shares of LivaNova during the 3rd quarter worth approximately $178,000. Institutional investors and hedge funds own 97.64% of the company's stock.

Wall Street Analyst Weigh In

Several analysts recently commented on LIVN shares. Needham & Company LLC reaffirmed a "buy" rating and set a $75.00 target price on shares of LivaNova in a report on Thursday. The Goldman Sachs Group initiated coverage on shares of LivaNova in a research note on Friday, October 4th. They issued a "buy" rating and a $65.00 price target on the stock. Robert W. Baird increased their price target on LivaNova from $66.00 to $72.00 and gave the stock an "outperform" rating in a research report on Thursday. Mizuho decreased their target price on shares of LivaNova from $80.00 to $70.00 and set an "outperform" rating on the stock in a report on Thursday. Finally, Stifel Nicolaus lifted their price target on LivaNova from $70.00 to $72.00 and gave the company a "buy" rating in a research note on Thursday, July 25th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $69.17.

LivaNova Trading Down 0.9 %

NASDAQ:LIVN traded down $0.49 during trading hours on Friday, hitting $51.13. 441,992 shares of the company were exchanged, compared to its average volume of 621,637. The stock has a market capitalization of $2.78 billion, a price-to-earnings ratio of 121.74 and a beta of 1.00. LivaNova PLC has a one year low of $42.75 and a one year high of $64.47. The company has a fifty day simple moving average of $51.13 and a 200 day simple moving average of $53.12. The company has a current ratio of 3.37, a quick ratio of 2.94 and a debt-to-equity ratio of 0.49.

LivaNova (NASDAQ:LIVN - Get Free Report) last posted its quarterly earnings data on Wednesday, July 31st. The company reported $0.81 EPS for the quarter, beating analysts' consensus estimates of $0.66 by $0.15. The company had revenue of $318.60 million for the quarter, compared to analyst estimates of $305.05 million. LivaNova had a net margin of 1.91% and a return on equity of 13.81%. Sell-side analysts expect that LivaNova PLC will post 2.58 EPS for the current fiscal year.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.